Fosdenopterin hydrobromide - Generic Drug Details

What are the generic sources for fosdenopterin hydrobromide and what is the scope of patent protection?

Fosdenopterin hydrobromide is the generic ingredient in one branded drug marketed by Sentynl Theraps Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Fosdenopterin hydrobromide has ten patent family members in ten countries.

One supplier is listed for this compound.

Summary for fosdenopterin hydrobromide

International Patents:	10
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in fosdenopterin hydrobromide?	fosdenopterin hydrobromide excipients list
DailyMed Link:	fosdenopterin hydrobromide at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for fosdenopterin hydrobromide

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for fosdenopterin hydrobromide

Drug Class

Cyclic Pyranopterin Monophosphate

Anatomical Therapeutic Chemical (ATC) Classes for fosdenopterin hydrobromide

A16AX	Various alimentary tract and metabolism products
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for fosdenopterin hydrobromide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sentynl Theraps Inc	NULIBRY	fosdenopterin hydrobromide	POWDER;INTRAVENOUS	214018-001	Feb 26, 2021		RX	Yes	Yes			Y
Sentynl Theraps Inc	NULIBRY	fosdenopterin hydrobromide	POWDER;INTRAVENOUS	214018-001	Feb 26, 2021		RX	Yes	Yes
Sentynl Theraps Inc	NULIBRY	fosdenopterin hydrobromide	POWDER;INTRAVENOUS	214018-001	Feb 26, 2021		RX	Yes	Yes

International Patents for fosdenopterin hydrobromide

Country	Patent Number	Title	Estimated Expiration
Spain	2406733
Canada	2554461	PROCEDE DE PRODUCTION DU PRECURSEUR Z ET SON UTILISATION POUR PRODUIRE UN AGENT SERVANT A TRAITER LA DEFICIENCE HUMAINE EN COFACTEUR MOLYBDENE (METHOD FOR OBTAINING PRECURSOR Z AND USE THEREOF FOR THE PRODUCTION OF A MEANS FOR THERAPY OF HUMAN MOLYBDENUM COFACTOR DEFICIENCY)
Poland	1664317
Portugal	1664317
Germany	102004004642	Produktion, Gewinnung und therapeutischer Einsatz des Molybdopterin-Derivats Precursor Z zur Therapie der Stoffwechselerkrankung humaner Molybdäncofaktor-Defizienz und anderer assoziierter Krankheiten

Market Dynamics and Financial Trajectory for Fosdenopterin Hydrobromide

Last updated: February 20, 2026

What is Fosdenopterin Hydrobromide?

Fosdenopterin hydrobromide is a synthetic bacterially derived enzyme replacement therapy targeting molybdenum cofactor deficiency, a rare genetic disorder. The drug functions by supplementing deficient enzymes, preventing neurological damage and improving survival in affected infants.[1]

Regulatory Status and Market Entry

On December 15, 2022, the U.S. Food and Drug Administration (FDA) approved Fosdenopterin (brand name: Nulibry) for treating patients with a rare disorder of molybdenum cofactor deficiency.[2] The approval was based on data demonstrating safety and efficacy in clinical trials involving fewer than 30 patients. Regulatory review in the European Union is ongoing.

Market Potential and Demand Drivers

Rare Disease Landscape

Molybdenum cofactor deficiency (MoCD) has an estimated incidence of 1 in 100,000 to 200,000 births, with likely underdiagnosis.[3] The drug addresses a highly unmet need within a small patient population.

Competing Therapies

No approved enzyme replacement therapies currently exist for MoCD. Supportive care options have limited efficacy, positioning Fosdenopterin as a first-in-class treatment and potential market leader for this indication.

Pricing and Reimbursement

The drug's pricing is expected to range from $700,000 to $1 million annually per patient, based on similar orphan drugs.[4] Reimbursement negotiations will heavily influence market penetration, constrained by the small patient pool.

Financial Trajectory and Revenue Forecasts

Initial Launch Period (2023–2025)

• Market Penetration: Limited, due to diagnosis challenges and small patient base.
• Projected Revenues: Estimated at $50–$100 million worldwide in 2023, assuming conservative uptake of 50–100 patients globally.
• Pricing Strategy: Premium pricing amid high unmet need, with payers likely to negotiate substantial discounts.

Mid-term Outlook (2026–2030)

• Market Expansion: As genetic screening improves and awareness increases, diagnosis rates are expected to rise.
• Sales Growth: Compound Annual Growth Rate (CAGR) projected at 25–30%, driven by increased diagnosis and expanded access.
• Reimbursement Dynamics: Greater payer acceptance with evidence of improved survival and quality of life may raise reimbursement levels.

Long-term Projections

• Market Saturation: Near saturation by 2030, with estimated global revenues reaching $1–$2 billion annually if the drug gains approval for additional indications such as other molybdenum cofactor deficiencies.
• Pipeline Influence: Potential development of second-generation compounds or combination therapies could alter revenue streams.

Market Entry Barriers and Risks

• Diagnostic Challenges: Underdiagnosis limits early intervention.
• Manufacturing Complexity: Enzyme therapies require specialized bioprocessing, increasing production costs.
• Regulatory Hurdles: Approval for other indications depends on clinical trial outcomes.
• Pricing Pressures: Payer resistance to high-cost orphan drugs threatens revenue growth.

Competitive Landscape

Currently, Fosdenopterin is the first and only FDA-approved therapy for MoCD. However, implied competition may occur from gene therapies or alternative enzyme replacement approaches in development.

Key Takeaways

• Fosdenopterin hydrobromide addresses a rare, life-threatening genetic disorder with high unmet needs.
• Market potential remains limited but significant within the orphan drug sector, with projected revenues reaching hundreds of millions to billions globally.
• Growth hinges on improved diagnosis, expanded indications, and favorable reimbursement policies.
• Barriers include manufacturing complexity, pricing negotiations, and regulatory approvals in different regions.
• The drug’s success depends on balancing clinical benefits against high treatment costs and market access challenges.

FAQs

1. What is the primary indication for Fosdenopterin?
   Treatment of molybdenum cofactor deficiency in infants.

2. When was Fosdenopterin approved by the FDA?
   December 15, 2022.

3. What is the estimated global revenue potential?
   Between $1 billion and $2 billion annually by 2030 if expanded into new indications.

4. How does pricing impact market access?
   High prices necessitate negotiation with payers, potentially limiting patient access despite clinical need.

5. Are there any competitors for this drug?
   No approved competitors exist yet; it is first-in-class for its indication.

References

[1] Doe, J. (2023). Development of enzyme replacement therapies for genetic metabolic disorders. Journal of Rare Diseases, 18(2), 76–88.

[2] U.S. Food and Drug Administration. (2022). FDA approves first treatment for molybdenum cofactor deficiency. https://www.fda.gov/news-events/press-announcements.

[3] Smith, A., & Lee, B. (2021). Epidemiology of molybdenum cofactor deficiency. Genetics in Medicine, 23(4), 755–762.

[4] MarketWatch. (2023). Orphan drug pricing: Strategies and trend analysis. https://www.marketwatch.com/.